p53 regulation Teamwork between RING domains of Mdm2 and MdmX

被引:40
|
作者
Wang, Xinjiang [1 ]
机构
[1] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
关键词
p53; Mdm2; MdmX; Mdm2/MdmX; MDM4; RING domains; protein stability; ubiquitination; lethality; knockout; knockin; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; UBIQUITIN LIGASE; EMBRYONIC LETHALITY; IN-VIVO; ANTAGONISTIC PLEIOTROPY; MDM2-DEFICIENT MICE; CELL SENESCENCE; QUIESCENT CELLS; ACTIVATES P53;
D O I
10.4161/cc.10.24.18662
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
p53 is a major tumor suppressor frequently inactivated through direct gene mutation and alternative mechanisms including overexpression of Mdm2 and MdmX. Both Mdm2 and MdmX are essential for negative regulation of p53 in vivo in a mutually dependent manner. The RING domain dependent E3 ligase activity of Mdm2 has been shown to be essential for negative regulation of p53. The prevailing model has dubbed MdmX as an inhibitor of p53 transcriptional activity through direct binding of its N-terminal domain to p53. However, recent findings established an essential role of the RING domain of MdmX in p53 degradation in vitro and in vivo. Biochemically, Mdm2 on its own is a monoubiquitination E3 ligase, however, MdmX can convert Mdm2 into a polyubiquitination E3 ligase necessary for p53 proteasomal degradation in cells, through their RING-RING interaction. While Mdm2 is the catalytic component of Mdm2/MdmX E3 complex, MdmX is both the activating component and a substrate of the holoenzyme. Knock-in of RING mutant MdmX in mice causes p53-dependent embryonic lethality in a similar manner as knockout of MdmX whole gene. These recent advancements in the field assigned an essential role of the RING domain of MdmX in negative regulation of p53 in vivo, just like Mdm2 RING domain, through p53 degradation.
引用
收藏
页码:4225 / 4229
页数:5
相关论文
共 50 条
  • [41] P53 degradation by Mdm2 - A novel mechanism for regulation of p53 stability
    Nampoothiri, VK
    CURRENT SCIENCE, 1998, 75 (09): : 875 - 877
  • [42] Targeting RING domains of Mdm2–MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells
    W Wu
    C Xu
    X Ling
    C Fan
    B P Buckley
    M V Chernov
    L Ellis
    F Li
    I G Muñoz
    X Wang
    Cell Death & Disease, 2015, 6 : e2035 - e2035
  • [43] P53 Mdm2 Inhibitors
    Khoury, Kareem
    Doemling, Alex
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (30) : 4668 - 4678
  • [44] Competitive Binding between Dynamic p53 Transactivation Subdomains to Human MDM2 Protein IMPLICATIONS FOR REGULATING THE p53.MDM2/MDMX INTERACTION
    Shan, Bing
    Li, Da-Wei
    Brueschweiler-Li, Lei
    Brueschweiler, Rafael
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (36) : 30376 - 30384
  • [45] MDM2与p53
    金晶
    刘耕陶
    癌症, 2001, (06) : 663 - 666
  • [46] MDM2 and BCL-2: to p53 or not to p53?
    Wang, Eunice S.
    BLOOD, 2023, 141 (11) : 1237 - 1238
  • [47] Binding of an inhibitor of the p53/MDM2 interaction to MDM2
    Duncan, SJ
    Cooper, MA
    Williams, DH
    CHEMICAL COMMUNICATIONS, 2003, (03) : 316 - 317
  • [48] Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53
    Lan Wang
    Guifen He
    Pingzhao Zhang
    Xiang Wang
    Mei Jiang
    Long Yu
    Molecular Biology Reports, 2011, 38 : 229 - 236
  • [49] p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
    Christine Wasylyk
    Roberto Salvi
    Manuela Argentini
    Christine Dureuil
    Isabelle Delumeau
    Joseph Abecassis
    Laurent Debussche
    Bohdan Wasylyk
    Oncogene, 1999, 18 : 1921 - 1934
  • [50] p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
    Wasylyk, C
    Salvi, R
    Argentini, M
    Dureuil, C
    Delumeau, I
    Abecassis, J
    Debussche, L
    Wasylyk, B
    ONCOGENE, 1999, 18 (11) : 1921 - 1934